TABLE OF CONTENTS
1 INTRODUCTION 20
1.1 OBJECTIVES OF THE STUDY 20
1.2 MARKET DEFINITION 20
1.3 OVERVIEW OF GLOBAL CANNABIS MARKET 20
1.4 LIMITATIONS 22
1.5 MARKETS COVERED 22
2 MARKET SEGMENTATION 24
2.1 MARKETS COVERED 24
2.2 GEOGRAPHICAL SCOPE 25
2.3 YEARS CONSIDERED FOR THE STUDY 26
2.4 CURRENCY AND PRICING 26
2.5 DBMR TRIPOD DATA VALIDATION MODEL 27
2.6 TECHNOLOGY LIFE LINE CURVE 30
2.7 MULTIVARIATE MODELLING 31
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 32
2.9 DBMR MARKET POSITION GRID 33
2.10 MARKET APPLICATION COVERAGE GRID 34
2.11 DBMR MARKET CHALLENGE MATRIX 35
2.12 VENDOR SHARE ANALYSIS 36
2.13 IMPORT-EXPORT DATA 37
2.14 SECONDARY SOURCES 38
2.15 ASSUMPTIONS 39
3 MARKET OVERVIEW 40
3.1 DRIVERS 42
3.1.1 LEGALIZATION OF MEDICAL AND RECREATIONAL USE OF CANNABIS 42
3.1.2 MEDICAL ADVANTAGES OF CANNABIS 43
3.1.3 HIGH ADAPTATION OF CANNABIS FOR RECREATIONAL PURPOSES 44
3.1.4 INCREASED APPLICATIONS OF CANNABIS IN SECTORS OTHER THAN MEDICAL 45
3.2 RESTRAINTS 46
3.2.1 UNCLEAR REGULATORY ENVIRONMENT 46
3.2.2 SCARCITY OF WATER AND SUSTAINABLE AGRICULTURE 47
3.2.3 LACK OF AWARENESS RELATED TO BENEFITS OF CANNABIS 47
3.2.4 MARKETING AND ADVERTISEMENT RESTRICTIONS 48
3.3 OPPORTUNITIES 49
3.3.1 STANDARDIZATION IN CULTIVATION PRACTICES 49
3.3.2 INNOVATION IN VAREITY OF SATIVA PRODUCTS 50
3.3.3 LAUNCHING OF FROZEN CANNABIS BUDS 50
3.4 CHALLENGES 51
3.4.1 MEETING THE PREDICTIVE DEMAND POST-LEGALIZATION 51
3.4.2 HIGH TAXES IMPOSED ON CANNABIS 51
3.4.3 STRINGENT TRANSPORTATION AND STORAGE NORMS INCREASES WAREHOUSING COST 51
4 EXECUTIVE SUMMARY 53
5 PREMIUM INSIGHTS 56
6 GLOBAL CANNABIS MARKET, BY PRODUCT TYPE 59
6.1 OVERVIEW 60
6.2 BUDS 62
6.3 TINCTURES 62
6.4 OIL 63
6.5 OTHERS 64
7 GLOBAL CANNABIS MARKET, BY USAGE 65
7.1 OVERVIEW 66
7.2 MEDICAL 67
7.2.1 CHRONIC PAIN 67
7.2.2 CANCER 67
7.2.3 MENTAL DISORDERS 68
7.2.4 OTHERS 68
7.3 RECREATIONAL 68
8 GLOBAL CANNABIS MARKET, BY CROP VAREITY 69
8.1 OVERVIEW 70
8.2 CANNABIS INDICA 71
8.3 CANNABIS SATIVA 71
8.4 OTHERS 72
9 GLOBAL CANNABIS MARKET, BY DISTRIBUTION CHANNEL 73
9.1 OVERVIEW 74
9.2 PHYSICAL 75
9.2.1 LICENSED PRIVATE RETAIL STORE 76
9.2.2 MANUFACTURER RETAIL STORE 76
9.2.3 GOVERNMENT RETAIL STORE 76
9.3 DIGITAL 76
9.3.1 MANUFACTURER WEBSITE 77
9.3.2 PRIVATE RETAIL WEBSITE 77
9.3.3 GOVERNMENT OPERATED WEBSITE 77
9.3.4 MANUFACTURER MOBILE APP 77
9.3.5 LICENSED PRIVATE RETAIL MOBILE APP 77
9.4 OTHERS 77
10 GLOBAL CANNABIS MARKET, BY GEOGRAPHY 78
10.1 OVERVIEW 79
10.2 NORTH AMERICA 84
10.2.1 U.S. 91
10.2.2 CANADA 93
10.3 EUROPE 96
10.3.1 GERMANY 103
10.3.2 NETHERLANDS 105
10.3.3 SWITZERLAND 107
10.3.4 REST OF EUROPE 110
10.4 ASIA-PACIFIC 111
10.4.1 AUSTRALIA 118
10.4.2 SOUTH KOREA 120
10.4.3 THAILAND 123
10.4.4 PHILIPPINES 125
10.4.5 REST OF ASIA-PACIFIC 127
10.5 SOUTH AMERICA 128
10.5.1 URUGUAY 135
10.5.2 BRAZIL 138
10.5.3 REST OF SOUTH AMERICA 140
10.6 MIDDLE EAST AND AFRICA 141
10.6.1 ZIMBABWE 148
10.6.2 REST OF MIDDLE EAST & AFRICA 150
11 GLOBAL CANNABIS MARKET, COMPANY LANDSCAPE 151
11.1 COMPANY SHARE ANALYSIS: GLOBAL 151
11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 152
11.3 COMPANY SHARE ANALYSIS: EUROPE 153
11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 154
11.5 MERGERS & ACQUISITIONS 155
11.6 NEW PRODUCT DEVELOPMENT & APPROVALS 156
11.7 EXPANSIONS 156
11.8 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS 157
11.9 REGULATIONS 158
12 SWOT ANALYSIS 161
12.1 DATA BRIDGE MARKET RESEARCH ANALYSIS 162
13 COMPANY PROFILES 163
13.1 AURORA CANNABIS 163
13.1.1 COMPANY SNAPSHOT 163
13.1.2 REVENUE ANALYSIS 163
13.1.3 COMPANY SHARE ANALYSIS 164
13.1.4 PRODUCT PORTFOLIO 164
13.1.5 PRODUCT PORTFOLIO OF CANNIMED LTD. (A SUBSIDIARY OF AURORA CANNABIS) 165
13.1.6 PRODUCT PORTFOLIO OF MEDRELEAF CORP. (A SUBSIDIARY OF AURORA CANNABIS) 166
13.1.7 RECENT DEVELOPMENTS 168
13.2 CANOPY GROWTH CORPORATION 169
13.2.1 COMPANY SNAPSHOT 169
13.2.2 REVENUE ANALYSIS 169
13.2.3 COMPANY SHARE ANALYSIS 170
13.2.4 PRODUCT PORTFOLIO 170
13.2.5 RECENT DEVELOPMENTS 170
13.3 THE SCOTTS COMPANY LLC 172
13.3.1 COMPANY SNAPSHOT 172
13.3.2 REVENUE ANALYSIS 172
13.3.3 COMPANY SHARE ANALYSIS 173
13.3.4 PRODUCT PORTFOLIO 173
13.3.5 RECENT DEVELOPMENT 173
13.4 TILRAY 174
13.4.1 COMPANY SNAPSHOT 174
13.4.2 REVENUE ANALYSIS 174
13.4.3 COMPANY SHARE ANALYSIS 175
13.4.4 PRODUCT PORTFOLIO 175
13.4.5 RECENT DEVELOPMENTS 175
13.5 THE CRONOS GROUP 176
13.5.1 COMPANY SNAPSHOT 176
13.5.2 REVENUE ANALYSIS 176
13.5.3 COMPANY SHARE ANALYSIS 177
13.5.4 PRODUCT PORTFOLIO 177
13.5.5 RECENT DEVELOPMENTS 178
13.6 O.PENVAPE 179
13.6.1 COMPANY SNAPSHOT 179
13.6.2 PRODUCT PORTFOLIO 179
13.6.3 RECENT DEVELOPMENTS 180
?
13.7 MARLEY NATURAL 181
13.7.1 COMPANY SNAPSHOT 181
13.7.2 PRODUCT PORTFOLIO 181
13.7.3 RECENT DEVELOPMENT 182
13.8 CARA THERAPEUTICS 183
13.8.1 COMPANY SNAPSHOT 183
13.8.2 REVENUE ANALYSIS 183
13.8.3 PRODUCT PORTFOLIO 184
13.8.4 RECENT DEVELOPMENTS 184
13.9 ARUMA LABS HOLDINGS PTY LIMITED 185
13.9.1 COMPANY SNAPSHOT 185
13.9.2 PRODUCT PORTFOLIO 185
13.9.3 RECENT DEVELOPMENTS 185
13.10 MEDCAN AUSTRALIA 186
13.10.1 COMPANY SNAPSHOT 186
13.10.2 PRODUCT PORTFOLIO 186
13.10.3 RECENT DEVELOPMENT 186
13.11 SUNDIAL GROWERS INC. 187
13.11.1 COMPANY SNAPSHOT 187
13.11.2 PRODUCT PORTFOLIO 187
13.11.3 RECENT DEVELOPMENT 188
13.12 GW PHARMACEUTICALS PLC 189
13.12.1 COMPANY SNAPSHOT 189
13.12.2 REVENUE ANALYSIS 189
13.12.3 PRODUCT PORTFOLIO 190
13.12.4 RECENT DEVELOPMENT 190
13.13 INSYS THERAPEUTICS, INC. 191
13.13.1 COMPANY SNAPSHOT 191
13.13.2 REVENUE ANALYSIS 191
13.13.3 PRODUCT PORTFOLIO 192
13.13.4 RECENT DEVELOPMENTS 192
13.14 APHRIA INC. 193
13.14.1 COMPANY SNAPSHOT 193
13.14.2 REVENUE ANALYSIS 193
13.14.3 PRODUCT PORTFOLIO 194
13.14.4 RECENT DEVELOPMENTS 197
13.15 VIVO CANNABIS 198
13.15.1 COMPANY SNAPSHOT 198
13.15.2 REVENUE ANALYSIS 198
13.15.3 PRODUCT PORTFOLIO 199
13.15.4 RECENT DEVELOPMENTS 202
13.16 CANNATREK 203
13.16.1 COMPANY SNAPSHOT 203
13.16.2 PRODUCT PORTFOLIO 203
13.16.3 RECENT DEVELOPMENT 203
14 QUESTIONNAIRE 204
15 CONCLUSION 209
16 REFERENCES 210
17 RELATED REPORTS 212